Emmanuel Hanon is the founder of Vicebio. Vicebio has raised $100M in total funding. Latest round: Series B. Based in London, UK.
Emmanuel Hanon is the CEO of Vicebio, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections. He leads the company in leveraging its proprietary Molecular Clamp technology to create next-generation multivalent respiratory virus vaccines.
Full founder directory · Investor directory · Company funding database · Fundraising library